Long-term data from DEVOTE/ONWARD studies show benefits of high dose nusinersen in people living with spinal muscular atrophy (SMA)New Phase 1b data further illustrate potential of salanersen in SMA, ...
Data presented at the 2026 Muscular Dystrophy Association meeting could have readthroughs to companies developing therapies for spinal muscular atrophy, Duchenne muscular dystrophy and Becker muscular ...
Genethon, a pioneer and leader in gene therapy for rare diseases, unveiled results at the MDA Conference in Orlando confirming the long-term efficacy of its GNT0004 gene therapy in Duchenne muscular ...
Annie Wilson learned to edit videos of adoptable dogs with her eyes because of her deep love for senior dogs at Muttville ...
Paul Wilson stashed an 'arsenal' of firearms in his bungalow after finding himself 'in a situation he couldn't get out of' ...
New Phase 1b data support the safety and effectiveness of salanersen over one year in children with SMA who had the potential for improvement due to suboptimal clinical status with prior gene ...
Biogen’s salanersen is now heading into three Phase III trials in SMA.
US biotech major Biogen has presented additional results from the Phase Ib study of salanersen, an investigational novel antisense oligonucleotide (ASO) given once a year for spinal muscular atrophy ...
Investigation Discovery’s The Curious Case Of… The Woman Dying for Attention examines how Sarah Delashmit faked cancer and other illnesses for years, faced federal fraud charges, and what her life ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The ability to rapidly test how specific DNA changes affect living systems is starting to ...
The Society for the Education of the Challenged (SEC) has been left anxious after receiving a notification from the state’s Welfare of Disabled Department directing the institution to shift its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results